Please login to the form below

Not currently logged in
Email:
Password:

Tafinlar

This page shows the latest Tafinlar news and features for those working in and with pharma, biotech and healthcare.

Novartis scores but Roche misses in melanoma trials

Novartis scores but Roche misses in melanoma trials

Novartis scores but Roche misses in melanoma trials. Phase III trial combo success for Tafinlar/Mekinist “unprecedented”. ... A phase III trial of Novartis Tafinlar and Mekinist has confirmed the potential of the pair in the post-surgical treatment

Latest news

  • Novartis gets lung cancer OK for Tafinlar/Mekinist combo Novartis gets lung cancer OK for Tafinlar/Mekinist combo

    Novartis gets lung cancer OK for Tafinlar/Mekinist combo. It can now be used to treat BRAF V600E-positive NSCLC patients in Europe. ... Novartis acquired Tafinlar and Mekinist as part of its asset-swap deal with GlaxoSmithKline (GSK) in 2015.

  • J&J gets CHMP backing for broader Darzalex use J&J gets CHMP backing for broader Darzalex use

    CHMP round-up. At its meeting last week the CHMP also gave its blessing to the combination of Novartis' Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF-positive non-small cell lung

  • The UK's new Cancer Drugs Fund The UK's new Cancer Drugs Fund

    Gaining the greenlight were Novartis' Zykadia (ceritinib) for lung cancer and melanoma combination Tafinlar (dabrafenib) and Mekinist (trametinib), and Servier's Lonsurf (trifluridine/tipiracil HCl) for bowel cancer.

  • Roche's melanoma combo Roche's melanoma combo "too expensive" for NHS use, says NICE

    NICE's decision hands an advantage in the UK market to Novartis' similar combination of MEK inhibitor Mekinist (trametinib) and BRAF inhibitor Tafinlar (dabrafenib), a duo which was acquired from GlaxoSmithKline ... The list price for a 28-day course of

  • Controversial new CDF promises Controversial new CDF promises "clearer, faster decision-making"

    The four new drugs added to the CDF are Novartis' Zykadia (ceritinib) for lung cancer and melanoma combination Tafinlar (dabrafenib) and Mekinist (trametinib), and Servier's Lonsurf (trifluridine/tipiracil HCl) for

More from news
Approximately 10 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    GSK's recently approved MEK inhibitor Mekinist and BRAF inhibitor Tafinlar will position Novartis to become a leader in the potential blockbuster market for metastatic melanoma, neglected by their current portfolio.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CMR

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics